OXSORALEN-ULTRA
LOE ApproachingNDAORALCAPSULE
Approved
Oct 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OXSORALEN-ULTRA is an oral capsule formulation approved in 1986 by Bausch + Lomb for an undisclosed indication. The specific mechanism of action and therapeutic class are not documented in available data.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%), signaling a transition phase requiring focused retention strategies rather than growth-mode expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and an approaching LOE, career opportunities on OXSORALEN-ULTRA are limited and may focus on mature-market management or transition planning. Professionals considering this product should expect stable but non-growth-oriented roles with potential for restructuring.
Brand ManagerField Sales Representative
Worked on OXSORALEN-ULTRA at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.